Valuation: Defence Therapeutics Inc.

Market Cap 26.9M 19.08M 17.12M 15.64M 14.28M 1.79B 27.75M 189M 75.19M 957M 71.63M 70.1M 3.02B P/E 2025
-9.9x
P/E 2026 -4x
Enterprise Value 26.74M 18.97M 17.01M 15.55M 14.19M 1.78B 27.59M 187M 74.74M 952M 71.2M 69.68M 3B EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
90.28%
Yield 2025 *
-
Yield 2026 -
1 day+1.43%
1 week+1.43%
Current month+1.43%
1 month-8.97%
3 months-13.41%
6 months-33.02%
Current year-50.69%
1 week 0.28
Extreme 0.285
0.37
1 month 0.28
Extreme 0.285
0.42
Current year 0.28
Extreme 0.285
0.74
1 year 0.28
Extreme 0.285
0.93
3 years 0.28
Extreme 0.285
2.9
5 years 0.28
Extreme 0.285
6.5
10 years 0.28
Extreme 0.285
8.15
Manager TitleAgeSince
Chief Executive Officer - 01/08/2026
Director of Finance/CFO 55 20/12/2024
Chief Operating Officer - 17/08/2026
Director TitleAgeSince
Chairman 53 01/08/2026
Director/Board Member - 27/09/2024
Director/Board Member - 16/09/2025
Date Insider Type Main position Quantity % Market Cap. Importance
9/29/26 A Option

Director

400,000 0.5278%
9/29/26 A Other

Director

0 0%
9/24/26 A Option

Founder

3,500,000 4.6181%
Change 5-day change 1-year change 3-year change Capi.($)
+1.43%+1.43%-58.72%-87.54% 18.96M
-4.83%+3.51%+53.62%+61.75% 69.4B
-1.34%+2.98%+24.79%+100.18% 57.62B
+0.02%+1.07%+10.63%+76.66% 57.24B
+5.09%+9.89%+22.45%+107.48% 44.03B
+2.62%+1.68%+28.91%+37.01% 43.65B
+8.24%+0.51%+213.26%+792.66% 38.08B
-1.86%+10.13%+26.82%+53.22% 36.31B
-2.97%-9.84%+88.86%+76.17% 32.61B
-2.18%+7.06%+36.06%-4.95% 25.47B
Average +0.42%+3.80%+44.67%+121.26% 40.44B
Weighted average by Cap. +0.05%+4.26%+51.72%+136.65%

Financials

2025 2026
Net sales - -
Net income -3.52M -2.5M -2.24M -2.05M -1.87M -235M -3.63M -24.68M -9.84M -125M -9.38M -9.18M -396M -6.7M -4.75M -4.26M -3.89M -3.55M -446M -6.91M -46.92M -18.71M -238M -17.83M -17.44M -752M
Net Debt 272K 193K 173K 158K 144K 18.13M 280K 1.91M 760K 9.67M 724K 708K 30.53M -161K -114K -103K -93.8K -85.62K -10.76M -166K -1.13M -451K -5.74M -430K -420K -18.12M
Projected Income Statement - Annual - Defence Therapeutics Inc.
Logo Defence Therapeutics Inc.
Defence Therapeutics Inc. is a Canada-based clinical-stage biotechnology company. The Company is engaged in developing and engineering the antibody drug conjugates (ADC) products using its proprietary platform. Its principal business activity is the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The core of its therapeutics platform is the ACCUM technology, which enables precision delivery ADCs in their intact form to target cells. The Company is focused on research, development and advancement of the main products using its Accum technology, which include ADC targeting various cancers, Anti-cancer AccuTOX program, Mesenchymal stromal cell-based vaccine (ARM-X) targeting cancer, mRNA vaccination, Cervical cancer vaccine, and Radio-immunoconjugates (RIC) targeting various cancers.
Employees
-
Date Price Change Volume
06/11/26 CA$0.3550 +1.43% 18,228
05/11/26 CA$0.3500 +4.48% 44,500
04/11/26 CA$0.3350 -1.47% 6,050
03/11/26 CA$0.3400 +19.30% 68,500
02/11/26 CA$0.2850 -18.57% 109,500